Figure 1.

Esaxerenone dose dependently reduced mean changes in urinary albumin-to-creatinine ratio (UACR) from baseline to the end of treatment (A) and higher UACR remission rates were observed with esaxerenone 2.5- and 5-mg/d groups at the end of treatment (B). Data are geometric mean (point estimates) ±95% confidence interval (A); point estimate ± exact 95% CI (B). Among the participants in the full analysis set, those with UACR measurements at both weeks 11 and 12 were included in the calculation of the achievement rate of remission. ***P<0.001 versus placebo (A); ***P=0.004 versus placebo (B).